SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer (SMCI) is trending sharply lower following the indictment of a co-founder and other employees for allegedly conspiring to illegally export high-performance AI chips to China. While the company itself was not named as a defendant, investors and community members are actively debating the long-term impact on its partnerships, regulatory compliance, and overall credibility as this legal overhang casts significant uncertainty on its future operations.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing intense selling pressure driven by a combination of regulatory scrutiny from a widened NHTSA investigation into FSD software and growing skepticism regarding the timeline and profitability of its long-term robotics and robotaxi initiatives. The stock has become a focal point for active debate, with the community polarized between those positioning for a technical reversal or short squeeze and those arguing that the current valuation remains detached from cooling demand and increasing competitive headwinds.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is facing significant downward pressure as market participants react to geopolitical tensions and the looming expiration of massive options positions on a quad-witching day. The community is actively debating whether the current price action signals a deeper bear market correction or if it is merely a volatile setup for a potential rebound as investors look for technical support.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp. is trending as investors react to its recent NYSE uplisting and a significant government award, fueling speculation about its role in bolstering domestic critical mineral supply chains. The community is actively discussing potential breakout scenarios, debating short squeeze opportunities, and closely monitoring the stock's performance ahead of upcoming earnings.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. (ANNA) is generating intense community buzz as traders focus on its low float and potential as a key European natural gas supplier amidst ongoing geopolitical volatility. Investors are actively discussing the stock's susceptibility to sharp momentum swings and potential for a short squeeze, while highlighting its role in regional energy independence.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is currently trending following a significant beat on recent quarterly earnings and the issuance of strong fiscal guidance, bolstered by a massive backlog and increased demand for its defense and AI-integrated geospatial data. The community is actively discussing the stock's growth potential alongside other space-sector peers, with many highlighting institutional accumulation and the company's expanding strategic partnerships as key long-term catalysts.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Investors are navigating heightened volatility driven by geopolitical tensions in the Middle East and a significant 'quadruple witching' options expiration event. Market sentiment remains divided, with the community actively debating whether current pullbacks represent a structural bear market trend or a tactical opportunity for dip-buying.

iShares Trust - iShares Russell 2000 ETF

iShares Russell 2000 ETF

IWM is trending as small-cap investors navigate intense volatility fueled by Middle East tensions, rising oil prices, and uncertainty surrounding Federal Reserve interest rate policy. The community is deeply divided, with many debating the impact of the ongoing conflict on energy costs and economic growth, while others actively trade aggressive put options in anticipation of further downside or potential short-term relief rallies.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is currently attracting significant trading activity due to high investor interest in compound semiconductor materials, specifically indium phosphide, which is critical for AI infrastructure and optical networking. While the community is actively debating the stock's high valuation relative to its financials and the potential impact of China's export controls, many traders are closely monitoring price action for signs of a potential short squeeze or further momentum shifts.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. It offers Alpha, Beta, Gamma, and orbital transfer vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 27, 2017 and is headquartered in Cedar Park, TX.

Firefly Aerospace Inc.

Firefly Aerospace is trending as traders analyze the company's recent record revenue growth and positive full-year guidance alongside volatile price action. The community is actively debating the stock's future, focusing on the potential catalyst of a SpaceX IPO and the company's expanding role in the space supply chain, while navigating frustration over recent technical rejections and short-term price fluctuations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Following the transaction, Geert R. owns 120,815 shares of the company.&nbsp;</li><li>Cel-Sci is most known for its experimental cancer treatment called Multikine.</li><li>The company is currently preparing to conduct a confirmatory registration study for the treatment which will enroll 212 patients.</li></ul>Shares of CEL-SCI Corp. (CVM) rallied 7% on Monday after its CEO Kersten Geert R. purchased 38,023 shares of restricted stock directly from the Company.According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/725363/000123603026000002/xslF345X05/primary_doc.xml">filing</a> with the U.S. Securities and Exchange Commission, Geert made the purchase on Jan. 22 at the closing price on Jan 21 or $5.26 per share.This transaction amounts to about $200,000. Following the transaction, the CEO owns 120,815 shares of the company.<h2 class="st-heading-2">Cel-Sci’s Pipeline</h2>Cel-Sci is known for its experimental cancer treatment, Multikine. It is designed to help the immune system "target" the tumor before surgery, radiation and chemotherapy.The company is currently preparing to conduct a confirmatory registration study for the treatment which will enroll 212 patients with newly diagnosed locally advanced not yet treated resectable head and neck cancer. Enrollment is expected to begin for the trial in spring 2026 and the company intends to seek approval based on data generated by 2028.During the fiscal year ended September, the company reported a net loss of $25.4 million, down from the $27.6 million reported in fiscal 2024.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CVM stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user said the stock is one to “watch closely.”<stembedurl>https://www.stocktwits.com/topstockalerts/message/642897665</stembedurl>Another highlighted that Vanguard Group had previously disclosed ownership of the stock. “Big Money has moved in here for a reason,” they said.<stembedurl>https://www.stocktwits.com/itsverified/message/642877607</stembedurl><a href="https://stocktwits.com/symbol/CVM">CVM stock</a> has dropped nearly 54% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/iova-shares-jump-whats-retail-expecting/cmy76S5R4h0">IOVA Shares Jump 8% — What’s Retail Expecting?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Cel-Sci logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why DID CVM Shares Rally Over 7% Today?

According to a filing with the U.S. Securities and Exchange Commission, CEO Kersten Geert R. purchased 38,023 shares in the company on Jan. 22 at $5.26 per share.

Equity

According to a filing with the U.S. Securities and Exchange Commission, CEO Kersten Geert R. purchased 38,023 shares in the company on Jan. 22 at $5.26 per share.


Retail chatter picked up on Cel-Sci Corporation on Wednesday as investors awaited a key decision from the Saudi Food and Drug Authority (SFDA) on the company’s application for Breakthrough Medicine Designation for its cancer immunotherapy, Multikine.&nbsp;The ruling could come soon, as the SFDA’s 60-day review window is nearing its close.In August, Cel-Sci signed a Memorandum of Understanding with a leading Saudi pharmaceutical company, which submitted the application to the SFDA. A final commercialization agreement between the two partners is expected in the third quarter of 2025. The Saudi partner is also expected to facilitate reimbursement and accelerate Multikine’s sale and patient access in the Kingdom.The move has drawn growing interest from Saudi investment funds looking to back Multikine and Cel-Sci’s expansion across the Middle East and North Africa region.Multikine is designed to strengthen a patient’s immune system before surgery for newly diagnosed, untreated head and neck cancer. In a global Phase 3 study, the largest of its kind, the therapy improved five-year survival rates to 73% from 45% among patients receiving standard care alone, cutting the risk of death by half.If approved, Multikine would qualify for accelerated patient access and reimbursement under Saudi Arabia’s Breakthrough Medicine Program, which aims to fast-track treatments for serious or life-threatening diseases that meet unmet medical needs.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘high’ message volume.One user noted that Cel-Sci’s April update indicated the company was encouraged to seek conditional approval under the Breakthrough Therapy Designation. The filing was made around mid-August, suggesting a decision could be imminent.<stembedurl>https://stocktwits.com/NavyPatrol657/message/632324726</stembedurl>Another user expressed anticipation for an update from CEO Geert Kersten, while a third observed that the stock might remain subdued until the SFDA announcement.<stembedurl>https://stocktwits.com/prophet777/message/632356422</stembedurl><stembedurl>https://stocktwits.com/NoobFriendly/message/632216212</stembedurl><a href="https://stocktwits.com/symbol/CVM">CEL-SCI Corporation’s stock</a> has declined 18% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CEL-SCI Corporation’s stock (CVM) has declined 18% so far in 2025.| Image source: Getty Images

Retail Buzz Builds Around Cel-Sci Stock Ahead Of Saudi Ruling On Cancer Drug Multikine

Multikine is a cancer immunotherapy, which has significantly improved survival in head and neck cancer patients during global Phase 3 trials.

CEL-SCI Corporation (CVM) on Friday announced it has reached an agreement with one of Saudi Arabia’s premier pharmaceutical companies for a partnership that spans regulatory and commercial activities for Multikine in the Kingdom of Saudi Arabia.<a href="https://stocktwits.com/symbol/CVM">CEL-SCI</a>’s shares were trading 33% higher at the time of writing.The formal agreement is expected to be signed with the Saudi pharmaceutical partner in the coming weeks, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250711051288/en/CEL-SCI-to-Sign-Partnership-Agreement-With-Leading-Saudi-Arabian-Pharma-Company-for-Multikine-in-the-Treatment-of-Head-Neck-Cancer">said</a>. The partner will then file a Breakthrough Medicine Designation application for Multikine with the Saudi Food and Drug Authority (SFDA).Multikine is a cancer drug administered before surgery as a treatment for newly diagnosed and previously untreated head and neck cancer.If granted Breakthrough Medicine Designation, Multikine would immediately become available for patient access, reimbursement, or sale in Saudi Arabia. CEL-SCI said that it believes Multikine meets all requirements for Breakthrough Medicine Designation as published by the SFDA and is now developing a comprehensive commercialization plan with its Saudi pharma partner.In a study spanning 20 countries, Multikine increased the 5-year survival rate of the target patient population to 73% versus 45% in patients treated with standard of care alone. The 5-year risk of death was halved from 55% to 27%.The drug, given right after diagnosis and before surgery, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.CEL-SCI also said on Friday that several Saudi funds have expressed interest in investing in Multikine, CEL-SCI, and/or a potential joint venture to serve the wider Middle East and North Africa (MENA) market.On Stocktwits, retail sentiment around CVM jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_11_at_11_59_25_AM_png_2f84b0779d.webp" alt="CVM's Sentiment Meter and Message Volume as of 12 p.m. ET on July 11, 2025 | Source: Stocktwits" width="625" height="63"><figcaption>CVM's Sentiment Meter and Message Volume as of 12 p.m. ET on July 11, 2025 | Source: Stocktwits</figcaption></figure>CVM stock is down by 58% this year and by over 86% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/meta-reportedly-stands-firm-on-eu-ad-model/ch8cirOR5Zw">Meta Reportedly Stands Firm On EU Ad Model Amid Looming Regulatory Penalties</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

CEL-SCI Stock Soars On Imminent Partnership With Saudi Arabian Pharma Company For Cancer Drug: Retail’s Thrilled

The formal agreement is expected to be signed with the Saudi pharmaceutical partner in the coming weeks, CEL-SCI said.

Shares of Cel-Sci Corp ($CVM) slipped in the after-hours trading session on Friday following the company’s announcement of a share offering, with retail sentiment staying neutral. The purchase price of the offering, for its common stock par value of $0.01 per share, wasn’t immediately known. The last reported sale price of its stock was $0.70 per share. According to the company’s filing with the SEC, it is offering potential purchasers, along with related parties who own more than 4.99% of its outstanding common stock immediately following the consummation of this offering, the opportunity to purchase pre-funded warrants exercisable at an exercise price of $0.01 per share.The purchase price of each pre-funded warrant is equal to the price per share of common stock being sold to the public in this offering, minus $0.01, the statement said.The pre-funded warrants will be immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full, the statement added. For each warrant, the number of shares of common stock on offer will be decreased on a one-for-one basis.&nbsp; Retail sentiment on Stocktwits has been ‘neutral’ compared to a week ago. Message volumes have been in the normal range. &nbsp;<figure class="image"><img style="aspect-ratio:1256/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_30_at_11_21_09_AM_2d60d70bed.png" alt="Screenshot 2024-12-30 at 11.21.09 AM.png" width="1256" height="302"><figcaption>CVM sentiment meter and message volumes on Dec 29</figcaption></figure><stembedurl>https://stocktwits.com/phoenix31415/message/598120019</stembedurl>A ‘bearish’ commenter was not convinced on the terms.<stembedurl>https://stocktwits.com/ThaDreadPirate/message/598079934</stembedurl>The company has engaged ThinkEquity as the placement agent in connection with this offering.Cel-Sci develops immunotherapy products for the treatment of cancer and infectious diseases.Cel-Sci stock is down 77% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cel-Sci Stock Slips After Public Offering: Retail's Neutral

The purchase price of each pre-funded Warrant is equal to the price per share of common stock being sold to the public in this offering, minus $0.01.

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Current Price	$3.60
Prev Close	$3.66
Open	$3.71
Dividend Yield	0.00%
50-Day Moving Average	$4.80
Beta	0.99
Avg. Volume	48,693.00
PE Ratio	-0.71

52-Week High	$13.48
52-Week Low	$1.98
Market Capitalization	$30.96M
EPS (Annual)	-$6.27
Price to Book	2.77
Revenue Per Employee	N/A

CVM
Cel-Sci Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CVM News

CVMCel-Sci Corp